Antisense regulation of expression and transactivation functions of the tumorigenic HBx and c-myc genes

Biochemical and Biophysical Research Communications
Le Hung, Vijay Kumar

Abstract

Earlier we have shown that the X-myc transgenic mice develop hepatocellular carcinoma (HCC) due to co-expression of c-Myc and HBx protein of hepatitis B virus [R. Lakhtakia, V. Kumar, H. Reddi, M. Mathur, S. Dattagupta, S.K. Panda, Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: a sequential pathological evaluation. J. Gastroenterol. Hepatol. 18 (2003) 80-91]. With the aim to develop therapeutic strategies for HCC, we constructed several mono- and bicistronic antisense recombinants against HBx and c-myc genes to regulate their expression as well as transactivation function in a human hepatoma cell line. A dose-dependent inhibition in the expression levels of HBx and c-Myc was observed with monocistronic constructs. Likewise, the bicistronic recombinants also blocked the expression as well as transactivation functions of cognate genes with equal efficacy. Further, expression of the constituent genes from the X-myc transgene could also be inhibited by these antisense constructs in cell culture. Thus, our study points towards clinical implications of antisense regulation of tumor-promoting genes in the management of HCC.

References

Aug 1, 1990·FEBS Letters·J N MolA R Stuitje
Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·P J FarnhamR T Schimke
Aug 26, 1986·Nucleic Acids Research·S M Heywood
Nov 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·C M GormanB H Howard
Apr 1, 1984·Carcinogenesis·G Klein, E Klein
Jan 1, 1994·Annual Review of Microbiology·E G Wagner, R W Simons
Jan 5, 1996·Biochemical and Biophysical Research Communications·K MoriyaK Koike
May 28, 1996·Proceedings of the National Academy of Sciences of the United States of America·V KumarR Kumar
Aug 22, 2001·Lancet·I TammG Hartmann
Jan 10, 2003·Journal of Gastroenterology and Hepatology·Ritu LakhtakiaSubrat Kumar Panda
Mar 18, 2003·Nature Biotechnology·Rodrigo YelinGalit Rotman
Apr 16, 2003·European Journal of Biochemistry·Jens Kurreck
May 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Dimitri SemizarovStephen W Fesik
May 20, 2003·Nature Biotechnology·Aimee L JacksonPeter S Linsley
Aug 28, 2003·Nature Cell Biology·Carol A SledzBryan R G Williams
Dec 4, 2003·Nature Biotechnology·Lisa J Scherer, John J Rossi
Jan 30, 2004·Annual Review of Medicine·Stanley T Crooke
Apr 7, 2004·Differentiation; Research in Biological Diversity·Stephanie Pebernard, Richard D Iggo
Jan 26, 2005·Human Pathology·Mark A Feitelson
May 21, 2005·Nature Reviews. Cancer·Martin E Gleave, Brett P Monia
Jun 15, 2005·Annual Review of Biochemistry·Gisela StorzKaren M Wassarman
Aug 17, 2005·Current Pharmaceutical Design·Francesca Marietta Coppelli, Jennifer Rubin Grandis

❮ Previous
Next ❯

Citations

Jul 8, 2008·Biochemical and Biophysical Research Communications·Xiaohong LiuMinghua Zhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.